1-5 of 5
Sanjeev Redkar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A200: CBT-502 (TQB2450), a novel anti-PD-L1 antibody, demonstrates favorable activity in MC-38/H-11 murine colon and A375 human melanoma animal models

Zhao Wei, Ling Yang, Yingchun Li, Jiansheng Lu, Xiquan Zhang, Xin Tian, Jiping Zha, Ziyong Sun, Junzhuan Qiu, Zhun Wang, Mamatha Reddy, Gavin S. Choy, Sanjeev Redkar
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A200.
https://doi.org/10.1158/1535-7163.TARG-17-A200
Published: 01 January 2018
View article titled, Abstract A200: CBT-502 (TQB2450), a novel anti-PD-L1 antibody, demonstrates favorable activity in MC-38/H-11 murine colon and A375 human melanoma animal models
Journal Articles

S110, a 5-Aza-2′-Deoxycytidine–Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor In vivo and Can Reduce Tumor Growth

Jody C. Chuang, Steven L. Warner, David Vollmer, Hariprasad Vankayalapati, Sanjeev Redkar, David J. Bearss, Xiangning Qiu, Christine B. Yoo, Peter A. Jones
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (5): 1443–1450.
https://doi.org/10.1158/1535-7163.MCT-09-1048
Published: 09 May 2010
View article titled, S110, a 5-Aza-2′-Deoxycytidine–Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor <em>In vivo</em> and Can Reduce Tumor Growth
Open the PDF for S110, a 5-Aza-2′-Deoxycytidine–Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor <em>In vivo</em> and Can Reduce Tumor Growth in another window
Journal Articles

Abstract A190: In vivo activity of SGI‐110, a novel hypomethylating agent for treatment in hematology and solid malignancies

Jason Scholl, David Vollmer, Jared Bearss, Carissa Jones, Virgil McCarthy, Paul Severson, Sanjeev Redkar, Rajashree Joshi‐Hangal, Roger Inloes, Chongtie Shi, David Bearss
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A190.
https://doi.org/10.1158/1535-7163.TARG-09-A190
Published: 10 December 2009
View article titled, Abstract A190: <em>In vivo</em> activity of SGI‐110, a novel hypomethylating agent for treatment in hematology and solid malignancies
Journal Articles

Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes

Shannon M. Mumenthaler, Patricia Y.B. Ng, Amanda Hodge, David Bearss, Gregory Berk, Sarath Kanekal, Sanjeev Redkar, Pietro Taverna, David B. Agus, Anjali Jain
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (10): 2882–2893.
https://doi.org/10.1158/1535-7163.MCT-09-0293
Published: 12 October 2009
View article titled, Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes
Open the PDF for Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes in another window
Journal Articles

The decitabine-derived demethylating dinucleotide, S110 shows improved activity due to increased drug delivery and stability

Steven Warner, Adrianne Clifford, Krzysztof Swierczek, Hariprasad Vankayalapati, Paul Severson, Jared Bearss, Jeremy Lamb, Donald Lavelle, Kestis Vaitkus, Joseph DiSimone, Chunlin Tang, Sanjeev Redkar, David Bearss
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B140.
Published: 01 November 2007
View article titled, The decitabine-derived demethylating dinucleotide, S110 shows improved activity due to increased drug delivery and stability